Spooked investors unloaded their holdings sending the markets plummeting with the Dow crashing 365 points to 16,540. Nasdaq slumped 133 points to 4,702.
On the upside
Biocept (Nasdaq: BIOC) launched its prostate cancer detection and monitoring test that uses a patient's blood.
uniQure (Nasdaq: QURE) reported positive preliminary results from an ongoing PhaseI/II clinical trial of AMT-060 in adult hemophilia B patients.
J.C. Penney (NYSE: JCP) reported a strong 3.9% increase in same store sales during the holiday months of November and December.
On the downside
TetraLogic Pharmaceuticals (Nasdaq: TLOG) reported disappointing results from a Phase 2 study of birinapant to treat myelodysplastic syndromes.
Caladrius Biosciences (Nasdaq: CLBS) discontinued a Phase 3 study of CLBS20 to treat metastatic melanoma and will direct more resources to its cell therapy development subsidiary PCT.
Shares of California Resources (NYSE: CRC) dropped as crude oil prices continued to fall.
In the broad market, declining issues outpaced advancers by a margin of nearly 7 to 1 on the NYSE and by 6 to 1 on Nasdaq. The broader S&P 500 sank 42 points to 1,948. Bitcoin soared $21 to $452.